{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T01:35:07Z","timestamp":1785202507000,"version":"3.55.0"},"reference-count":179,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.bbcan.2020.188486","type":"journal-article","created":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T13:41:04Z","timestamp":1606830064000},"page":"188486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Peptides that immunoactivate the tumor microenvironment"],"prefix":"10.1016","volume":"1875","author":[{"given":"Natsuki","family":"Furukawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander S.","family":"Popel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2020.188486_bb0005","first-page":"1","article-title":"Clinical efficacy and safety of anti-PD-1\/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis","volume":"10","author":"Sun","year":"2020","journal-title":"Sci. Rep."},{"issue":"e200423","key":"10.1016\/j.bbcan.2020.188486_bb0010","article-title":"Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.bbcan.2020.188486_bb0015","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2020.188486_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold tumors: a therapeutic challenge for immunotherapy","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0025","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.3389\/fimmu.2018.02909","article-title":"Immunomodulation of the tumor microenvironment: turn foe into friend","volume":"9","author":"Locy","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0030","first-page":"1","article-title":"Turning cold into hot: firing up the tumor microenvironment","author":"Duan","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bbcan.2020.188486_bb0035","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.trecan.2020.02.003","article-title":"Cancer epigenetics, tumor immunity, and immunotherapy","volume":"6","author":"Cao","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bbcan.2020.188486_bb0040","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2020.188486_bb0045","first-page":"57","article-title":"Factors determining antibody distribution in tumors","volume":"29","author":"Thurber","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bbcan.2020.188486_bb0050","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of monoclonal antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2008.04.012","article-title":"Antibody tumor penetration","volume":"60","author":"Thurber","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbcan.2020.188486_bb0060","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1476-5381.2009.00190.x","article-title":"Therapeutic antibodies: successes, limitations and hopes for the future","volume":"157","author":"Chames","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0065","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2020.188486_bb0070","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0075","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1158\/1535-7163.MCT-18-0737","article-title":"A rationally designed peptide antagonist of the PD-1 signaling pathway as an immunomodulatory agent for cancer therapy","volume":"18","author":"Sasikumar","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2020.188486_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-017-0328-x","article-title":"Evaluation of the use of therapeutic peptides for cancer treatment","volume":"24","author":"Marqus","year":"2017","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.bbcan.2020.188486_bb0085","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tips.2017.01.003","article-title":"Cell-penetrating peptides: from basic research to clinics","volume":"38","author":"Guidotti","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bbcan.2020.188486_bb0090","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00726-017-2516-0","article-title":"Thirteen decades of peptide synthesis: key developments in solid phase peptide synthesis and amide bond formation utilized in peptide ligation","volume":"50","author":"Jaradat","year":"2018","journal-title":"Amino Acids"},{"key":"10.1016\/j.bbcan.2020.188486_bb0095","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nri.2017.131","article-title":"Towards personalized, tumour-specific, therapeutic vaccines for cancer","volume":"18","author":"Hu","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0100","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1126\/science.aar7112","article-title":"Personalized vaccines for cancer immunotherapy","volume":"359","author":"Sahin","year":"2018","journal-title":"Science (80-. )"},{"key":"10.1016\/j.bbcan.2020.188486_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-019-1055-6","article-title":"Neoantigen vaccine: an emerging tumor immunotherapy","volume":"18","author":"Peng","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2020.188486_bb0110","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"1\u201319","key":"10.1016\/j.bbcan.2020.188486_bb0115","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2020.188486_bb0120","series-title":"Immunosuppression Modulating Compounds","author":"Sasikumar","year":"2014"},{"key":"10.1016\/j.bbcan.2020.188486_bb0125","series-title":"Macrocyclic Inhibitors of the PD-1\/PD-L1 and CD80(B7-1)\/PD-L1 Protein\/Protein Interactions","author":"Miller","year":"2016"},{"key":"10.1016\/j.bbcan.2020.188486_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/molecules24112071","article-title":"Development of the inhibitors that target the PD-1\/PD-L1 interaction\u2014a brief look at progress on small molecules, peptides and macrocycles","volume":"24","author":"Guzik","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.bbcan.2020.188486_bb0135","doi-asserted-by":"crossref","first-page":"13732","DOI":"10.1002\/anie.201707707","article-title":"Bioactive macrocyclic inhibitors of the PD-1\/PD-L1 immune checkpoint","volume":"56","author":"Magiera-Mularz","year":"2017","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.bbcan.2020.188486_bb0140","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.bbrc.2016.12.156","article-title":"Rapid PD-L1 detection in tumors with PET using a highly specific peptide","volume":"483","author":"Chatterjee","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbcan.2020.188486_bb0145","doi-asserted-by":"crossref","first-page":"64967","DOI":"10.18632\/oncotarget.11274","article-title":"Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2020.188486_bb0150","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.canlet.2018.04.031","article-title":"Rational design and development of a peptide inhibitor for the PD-1\/PD-L1 interaction","volume":"434","author":"Boohaker","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2020.188486_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms20030572","article-title":"Design and synthesis of A PD-1 binding peptide and evaluation of its anti-tumor activity","volume":"20","author":"Abbas","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2020.188486_bb0160","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1089\/ars.2010.3584","article-title":"Peroxiredoxin 5: structure, mechanism, and function of the mammalian atypical 2-Cys peroxiredoxin","volume":"15","author":"Knoops","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.bbcan.2020.188486_bb0165","doi-asserted-by":"crossref","first-page":"27189","DOI":"10.18632\/oncotarget.16089","article-title":"The antitumor activity and preliminary modeling on the potential mechanism of action of human peroxiredoxin-5","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2020.188486_bb0170","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00280-019-03995-z","article-title":"Discovery of hPRDX5-based peptide inhibitors blocking PD-1\/PD-L1 interaction through in silico proteolysis and rational design","volume":"85","author":"Zou","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0705-y","article-title":"Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy","volume":"7","author":"Liu","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2020.188486_bb0180","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1158\/2326-6066.CIR-17-0035","article-title":"Peptide blocking of PD-1\/PD-L1 interaction for cancer immunotherapy","volume":"6","author":"Li","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bbcan.2020.188486_bb0185","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1039\/C9CC00445A","article-title":"Developing native peptide-based radiotracers for PD-L1 PET imaging and improving imaging contrast by pegylation","volume":"55","author":"Kuan","year":"2019","journal-title":"Chem. Commun."},{"key":"10.1016\/j.bbcan.2020.188486_bb0190","doi-asserted-by":"crossref","first-page":"11760","DOI":"10.1002\/anie.201506225","article-title":"Blocking of the PD-1\/PD-L1 interaction by a D -peptide antagonist for cancer immunotherapy","volume":"54","author":"Chang","year":"2015","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.bbcan.2020.188486_bb0195","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1126\/science.271.5257.1854","article-title":"Identification of D-Peptide Ligands Through Mirror-Image Phage Display","volume":"271","author":"Schumacher","year":"1996","journal-title":"Science (80-. )"},{"key":"10.1016\/j.bbcan.2020.188486_bb0200","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1073\/pnas.1711837115","article-title":"Method to generate highly stable D-amino acid analogs of bioactive helical peptides using a mirror image of the entire PDB","volume":"115","author":"Garton","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2020.188486_bb0205","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1080\/10717544.2018.1509907","article-title":"PD-1\/PD-L1 pathway and angiogenesis dual recognizable nanoparticles for enhancing chemotherapy of malignant cancer","volume":"25","author":"Sun","year":"2018","journal-title":"Drug Deliv."},{"key":"10.1016\/j.bbcan.2020.188486_bb0210","first-page":"1","article-title":"A novel d-peptide identified by mirror-image phage display blocks TIGIT\/PVR for cancer immunotherapy","author":"Zhou","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.bbcan.2020.188486_bb0215","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/cei.13407","article-title":"TIGIT as an emerging immune checkpoint","volume":"200","author":"Harjunp\u00e4\u00e4","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0220","doi-asserted-by":"crossref","first-page":"119984","DOI":"10.1016\/j.biomaterials.2020.119984","article-title":"Phage display-identified PD-L1-binding peptides reinvigorate T-cell activity and inhibit tumor progression","volume":"247","author":"Gurung","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.bbcan.2020.188486_bb0225","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41589-018-0161-x","article-title":"HIP1R targets PD-L1 to lysosomal degradation to alter T cell\u2013mediated cytotoxicity","volume":"15","author":"Wang","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0230","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1021\/acschembio.9b00743","article-title":"An immune-stimulatory helix-loop-helix peptide: selective inhibition of CTLA-4-B7 interaction","volume":"15","author":"Mudiyanselage","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0235","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.apsb.2020.01.005","article-title":"A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses","volume":"10","author":"Zhai","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bbcan.2020.188486_bb0240","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/imr.12519","article-title":"LAG3 (CD223) as a cancer immunotherapy target","volume":"276","author":"Andrews","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.bbcan.2020.188486_bb0245","first-page":"1","article-title":"PD-1-targeted discovery of peptide inhibitors by virtual screening, molecular dynamics simulation, and surface plasmon resonance","volume":"24","author":"Wang","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.bbcan.2020.188486_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-10946-2","article-title":"Identification and validation of a PD-L1 binding peptide for determination of PDL1 expression in tumors","volume":"7","author":"Caldwell","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2020.188486_bb0255","article-title":"mRNA display discovery of a novel programmed death ligand 1 (PD-L1) binding peptide (a peptide ligand for PD-L1)","volume":"1","author":"Kamalinia","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0179201","article-title":"Design of short peptides to block BTLA\/HVEM interactions for promoting anticancer T-cell responses","volume":"12","author":"Spodzieja","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2020.188486_bb0265","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"Vignali","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0270","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/cas.14069","article-title":"Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target?","volume":"110","author":"Ohue","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbcan.2020.188486_bb0275","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nri.2017.75","article-title":"The regulation of immune tolerance by FOXP3","volume":"17","author":"Lu","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0280","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1002\/eji.201847659","article-title":"Targeting Treg cells in cancer immunotherapy","volume":"49","author":"Tanaka","year":"2019","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0285","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/ni.2402","article-title":"Transcription factor Foxp3 and its protein partners form a complex regulatory network","volume":"13","author":"Rudra","year":"2012","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0290","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.4049\/jimmunol.1001114","article-title":"A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice","volume":"185","author":"Casares","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0295","doi-asserted-by":"crossref","first-page":"71709","DOI":"10.18632\/oncotarget.17845","article-title":"Blockage of FOXP3 transcription factor dimerization and FOXP3\/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor","volume":"8","author":"Lozano","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2020.188486_bb0300","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nature05673","article-title":"Foxp3 controls regulatory T-cell function by interacting with AML1\/Runx1","volume":"446","author":"Ono","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2020.188486_bb0305","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.4049\/jimmunol.1402997","article-title":"Inhibition of FOXP3\/NFAT interaction enhances T cell function after TCR stimulation","volume":"195","author":"Lozano","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0310","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.cell.2006.05.042","article-title":"FOXP3 controls regulatory T cell function through cooperation with NFAT","volume":"126","author":"Wu","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2020.188486_bb0315","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","article-title":"Wnt\/\u03b2-catenin signaling: components, mechanisms, and diseases","volume":"17","author":"MacDonald","year":"2009","journal-title":"Dev. Cell"},{"key":"10.1016\/j.bbcan.2020.188486_bb0320","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"Muzny","year":"2012","journal-title":"Nature"},{"issue":"1\u201319","key":"10.1016\/j.bbcan.2020.188486_bb0325","article-title":"A review of the role of wnt in cancer immunomodulation","volume":"11","author":"Goldsberry","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2020.188486_bb0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2019.02293","article-title":"WNT\/\u03b2-catenin signaling pathway regulating T cell-inflammation in the tumor microenvironment","volume":"10","author":"Li","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0335","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.immuni.2013.07.019","article-title":"Canonical Wnt signaling negatively modulates regulatory T cell function","volume":"39","author":"van Loosdregt","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.bbcan.2020.188486_bb0340","doi-asserted-by":"crossref","first-page":"9534","DOI":"10.1021\/bi900770z","article-title":"Analysis of the interaction of BCL9 with \u03b2-catenin and development of fluorescence polarization and surface plasmon resonance binding assays for this interaction","volume":"48","author":"Kawamoto","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbcan.2020.188486_bb0345","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1038\/emboj.2012.150","article-title":"The many faces and functions of \u00ce 2-catenin","volume":"31","author":"Valenta","year":"2012","journal-title":"EMBO J."},{"key":"10.1016\/j.bbcan.2020.188486_bb0350","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1242\/jcs.02864","article-title":"Nucleo-cytoplasmic distribution of \u03b2-catenin is regulated by retention","volume":"119","author":"Krieghoff","year":"2006","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bbcan.2020.188486_bb0355","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.csbj.2019.01.012","article-title":"Stapled peptides inhibitors: a new window for target drug discovery","volume":"17","author":"Ali","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.bbcan.2020.188486_bb0360","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1021\/jm201125d","article-title":"Design of triazole-stapled BCL9 \u03b1-helical peptides to target the \u03b2-catenin\/B-cell CLL\/lymphoma 9 (BCL9) protein-protein interaction","volume":"55","author":"Kawamoto","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbcan.2020.188486_bb0365","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003808","article-title":"Targeted disruption of the BCL9\/ -catenin complex inhibits oncogenic Wnt signaling","volume":"4","author":"Takada","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbcan.2020.188486_bb0370","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aau5240","article-title":"Pharmacological inhibition of \u03b2-catenin\/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells","volume":"5","author":"Feng","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbcan.2020.188486_bb0375","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/gutjnl-2013-306253","article-title":"CCL20\/CCR6-mediated migration of regulatory T cells to the Helicobacter pylori-infected human gastric mucosa","volume":"63","author":"Cook","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.bbcan.2020.188486_bb0380","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2020.188486_bb0385","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1043-4666(03)00101-7","article-title":"A synthetic peptide from transforming growth factor \u03b2 type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury","volume":"22","author":"Ezquerro","year":"2003","journal-title":"Cytokine"},{"key":"10.1016\/j.bbcan.2020.188486_bb0390","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cyto.2007.06.004","article-title":"Identification of peptide inhibitors of transforming growth factor beta 1 using a phage-displayed peptide library","volume":"39","author":"Dotor","year":"2007","journal-title":"Cytokine"},{"key":"10.1016\/j.bbcan.2020.188486_bb0395","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1600-065X.2007.00565.x","article-title":"\u2018Yin-Yang\u2019 functions of transforming growth factor-\u03b2 and T regulatory cells in immune regulation","volume":"220","author":"Wan","year":"2007","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.bbcan.2020.188486_bb0400","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.4049\/jimmunol.172.9.5149","article-title":"Cutting edge: TGF-\u03b2 induces a regulatory phenotype in CD4 + CD25 \u2212 T cells through Foxp3 induction and down-regulation of Smad7","volume":"172","author":"Fantini","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0405","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4049\/jimmunol.181.1.126","article-title":"In vitro and in vivo down-regulation of regulatory T cell activity with a peptide inhibitor of TGF-\u03b21","volume":"181","author":"Gil-Guerrero","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0410","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1002\/ijc.24656","article-title":"Peptide inhibitors of transforming growth factor-\u03b2 enhance the efficacy of antitumor immunotherapy","volume":"125","author":"Llopiz","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2020.188486_bb0415","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature12428","article-title":"Regulatory T cell stability is maintained by a neuropilin-1:semaphorin-4a axis","volume":"501","author":"Delgoffe","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2020.188486_bb0420","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jconrel.2015.08.016","article-title":"Immunoglobulin Fc-fused, neuropilin-1-specific peptide shows efficient tumor tissue penetration and inhibits tumor growth via anti-angiogenesis","volume":"216","author":"Kim","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbcan.2020.188486_bb0425","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1158\/2326-6066.CIR-19-0143","article-title":"A neuropilin-1 antagonist exerts antitumor immunity by inhibiting the suppressive function of intratumoral regulatory T cells","volume":"8","author":"Jung","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bbcan.2020.188486_bb0430","doi-asserted-by":"crossref","first-page":"77110","DOI":"10.18632\/oncotarget.20363","article-title":"Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer","volume":"8","author":"Santagata","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2020.188486_bb0435","doi-asserted-by":"crossref","first-page":"8369","DOI":"10.1021\/acs.jmedchem.6b00695","article-title":"Exploring the N-terminal region of C-X-C motif chemokine 12 (CXCL12): identification of plasma-stable cyclic peptides as novel, potent C-X-C chemokine receptor type 4 (CXCR4) antagonists","volume":"59","author":"Di Maro","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbcan.2020.188486_bb0440","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejca.2012.05.005","article-title":"A review on CXCR4\/CXCL12 axis in oncology: no place to hide","volume":"49","author":"Domanska","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbcan.2020.188486_bb0445","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.3389\/fimmu.2018.02159","article-title":"The role of CXC chemokine receptors 1-4 on immune cells in the tumor microenvironment","volume":"9","author":"Susek","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2019.01205","article-title":"Cancer immunotherapy based on natural killer cells: current progress and new opportunities","volume":"10","author":"Hu","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0455","doi-asserted-by":"crossref","first-page":"12628","DOI":"10.1073\/pnas.192301899","article-title":"Antiviral and antitumor peptides from insects","volume":"99","author":"Chernysh","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2020.188486_bb0460","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.intimp.2011.10.016","article-title":"Anti-tumor activity of immunomodulatory peptide alloferon-1 in mouse tumor transplantation model","volume":"12","author":"Chernysh","year":"2012","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0465","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.imbio.2012.12.002","article-title":"The effect of alloferon on the enhancement of NK cell cytotoxicity against cancer via the up-regulation of perforin\/granzyme B secretion","volume":"218","author":"Bae","year":"2013","journal-title":"Immunobiology"},{"key":"10.1016\/j.bbcan.2020.188486_bb0470","doi-asserted-by":"crossref","first-page":"10160","DOI":"10.1073\/pnas.0913745107","article-title":"Peptide antagonism as a mechanism for NK cell activation","volume":"107","author":"Fadda","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2020.188486_bb0475","doi-asserted-by":"crossref","first-page":"6166","DOI":"10.4049\/jimmunol.164.12.6166","article-title":"M-1\/M-2 macrophages and the Th1\/Th2 paradigm","volume":"164","author":"Mills","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0480","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2014.00514","article-title":"From monocytes to M1\/M2 macrophages: phenotypical vs. functional differentiation","volume":"5","author":"Italiani","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0485","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1172\/JCI59643","article-title":"Macrophage plasticity and polarization: in vivo veritas","volume":"122","author":"Sica","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2020.188486_bb0490","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0495","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","article-title":"Macrophage activation and polarization: nomenclature and experimental guidelines","volume":"41","author":"Murray","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.bbcan.2020.188486_bb0500","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"issue":"97\u2013111","key":"10.1016\/j.bbcan.2020.188486_bb0505","article-title":"Tumor-associated macrophages as target for antitumor therapy","volume":"66","author":"Sawa-Wejksza","year":"2018","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.bbcan.2020.188486_bb0510","doi-asserted-by":"crossref","first-page":"15919","DOI":"10.1073\/pnas.1312197110","article-title":"Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival","volume":"110","author":"Cieslewicz","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2020.188486_bb0515","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0193015","article-title":"Selective targeting of tumor associated macrophages in different tumor models","volume":"13","author":"Kakoschky","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2020.188486_bb0520","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11095-019-2596-5","article-title":"Surface modification of polymeric nanoparticles with M2pep peptide for drug delivery to tumor-associated macrophages","volume":"36","author":"Pang","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bbcan.2020.188486_bb0525","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jconrel.2020.02.011","article-title":"Remodeling tumor immune microenvironment via targeted blockade of PI3K-\u03b3 and CSF-1\/CSF-1R pathways in tumor associated macrophages for pancreatic cancer therapy","volume":"321","author":"Li","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbcan.2020.188486_bb0530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-14709-x","article-title":"Precision targeting of tumor macrophages with a CD206 binding peptide","volume":"7","author":"Scodeller","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2020.188486_bb0535","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.canlet.2017.05.010","article-title":"Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy","volume":"402","author":"Rady","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2020.188486_bb0540","doi-asserted-by":"crossref","first-page":"54951","DOI":"10.18632\/oncotarget.18627","article-title":"Melittin suppresses tumor progression by regulating tumorassociated macrophages in a Lewis lung carcinoma mouse model","volume":"8","author":"Lee","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2020.188486_bb0545","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0610-4","article-title":"Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide","volume":"7","author":"Lee","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2020.188486_bb0550","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aax6337","article-title":"Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses","volume":"12","author":"Jaynes","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbcan.2020.188486_bb0555","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.1158\/0008-5472.CAN-09-4672","article-title":"Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes","volume":"70","author":"Movahedi","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2020.188486_bb0560","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1111\/j.1582-4934.2008.00189.x","article-title":"Phage display selection of peptides that home to atherosclerotic plaques: IL-4 receptor as a candidate target in atherosclerosis","volume":"12","author":"Hong","year":"2008","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.bbcan.2020.188486_bb0565","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1158\/1535-7163.MCT-17-0339","article-title":"IL4 receptor\u2013targeted proapoptotic peptide blocks tumor growth and metastasis by enhancing antitumor immunity","volume":"16","author":"Vadevoo","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2020.188486_bb0570","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1371\/journal.pone.0074548","article-title":"Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases","volume":"8","author":"Portella","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2020.188486_bb0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-016-0326-y","article-title":"Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model","volume":"35","author":"Mercurio","year":"2016","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2020.188486_bb0580","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0585","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2020.00924","article-title":"Dendritic cells and their role in immunotherapy","volume":"11","author":"Gardner","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0590","doi-asserted-by":"crossref","first-page":"40437","DOI":"10.18632\/oncotarget.9624","article-title":"A novel peptide targeting Clec9a on dendritic cell for cancer immunotherapy","volume":"7","author":"Yan","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2020.188486_bb0595","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1182\/blood-2008-05-155176","article-title":"The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement","volume":"112","author":"Caminschi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2020.188486_bb0600","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1172\/JCI34584","article-title":"Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin","volume":"118","author":"Sancho","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2020.188486_bb0605","doi-asserted-by":"crossref","first-page":"16693","DOI":"10.1074\/jbc.M709923200","article-title":"CLEC9A is a novel activation C-type lectin-like receptor expressed on BDCA3+ dendritic cells and a subset of monocytes","volume":"283","author":"Huysamen","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2020.188486_bb0610","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.semcdb.2014.05.016","article-title":"BDCA3+CLEC9A+ human dendritic cell function and development","volume":"41","author":"van der Aa","year":"2015","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0615","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3934\/Allergy.2017.4.207","article-title":"CLEC receptors, endocytosis and calcium signaling","volume":"1","author":"Cote","year":"2017","journal-title":"AIMS Allergy Immunol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0620","doi-asserted-by":"crossref","DOI":"10.1152\/ajpcell.00039.2011","article-title":"Ca2+ signaling in the regulation of dendritic cell functions","volume":"300","author":"Shumilina","year":"2011","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0625","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-0500-2-23","article-title":"A biologically active peptide mimetic of N-acetylgalactosamine\/galactose","volume":"2","author":"Eggink","year":"2009","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.bbcan.2020.188486_bb0630","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0339-5","article-title":"An innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides","volume":"6","author":"Eggink","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2020.188486_bb0635","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.intimp.2018.04.025","article-title":"New peptide MY1340 revert the inhibition effect of VEGF on dendritic cells differentiation and maturation via blocking VEGF-NRP-1 axis and inhibit tumor growth in vivo","volume":"60","author":"Mo","year":"2018","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0640","first-page":"619","article-title":"Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells","volume":"2","author":"Rotonda","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2020.188486_bb0645","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1182\/blood.V92.11.4150","article-title":"Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo","volume":"92","author":"Gabrilovich","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2020.188486_bb0650","first-page":"2963","article-title":"Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function","volume":"5","author":"Gabrilovich","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2020.188486_bb0655","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.4049\/jimmunol.1601116","article-title":"VEGF requires the receptor NRP-1 to inhibit lipopolysaccharide-dependent dendritic cell maturation","volume":"197","author":"Oussa","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0660","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0665","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1007\/s00262-015-1766-5","article-title":"Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination","volume":"64","author":"Hansen","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bbcan.2020.188486_bb0670","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1158\/0008-5472.CAN-15-3164","article-title":"Accumulation of MDSC and Th17 cells in patients with metastatic colorectal cancer predicts the efficacy of a FOLFOX-bevacizumab drug treatment regimen","volume":"76","author":"Limagne","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2020.188486_bb0675","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.3892\/ol.2017.6305","article-title":"Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer","volume":"14","author":"Gonda","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bbcan.2020.188486_bb0680","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nm.3560","article-title":"Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice","volume":"20","author":"Qin","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2020.188486_bb0685","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00398","article-title":"Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression","volume":"9","author":"Fleming","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0690","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0695","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.semradonc.2014.07.005","article-title":"Radiotherapy and immunogenic cell death","volume":"25","author":"Golden","year":"2015","journal-title":"Semin. Radiat. Oncol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0700","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/cddis.2016.47","article-title":"The oncolytic peptide LTX-315 triggers immunogenic cell death","volume":"7","author":"Zhou","year":"2016","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2020.188486_bb0705","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1074\/jbc.M111.279281","article-title":"Relative spatial positions of tryptophan and cationic residues in helical membrane-active peptides determine their cytotoxicity","volume":"287","author":"Rekdal","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2020.188486_bb0710","doi-asserted-by":"crossref","first-page":"26599","DOI":"10.18632\/oncotarget.5613","article-title":"The oncolytic peptide LTX-315 kills cancer cells through Bax\/Bak-regulated mitochondrial membrane permeabilization","volume":"6","author":"Zhou","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2020.188486_bb0715","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00262-014-1540-0","article-title":"Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315","volume":"63","author":"Camilio","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bbcan.2020.188486_bb0720","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/cdd.2016.35","article-title":"The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade","volume":"23","author":"Yamazaki","year":"2016","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bbcan.2020.188486_bb0725","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-018-1092-x","article-title":"Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model","volume":"21","author":"Camilio","year":"2019","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bbcan.2020.188486_bb0730","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1200\/JCO.2018.36.15_suppl.3094","article-title":"A phase I\/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors","volume":"36","author":"Spicer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0735","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0148980","article-title":"The cytolytic amphipathic \u03b2(2,2)-amino acid LTX-401 induces DAMP release in melanoma cells and causes complete regression of B16 melanoma","volume":"11","author":"Eike","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2020.188486_bb0740","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1038\/cdd.2016.86","article-title":"The oncolytic compound LTX-401 targets the Golgi apparatus","volume":"23","author":"Zhou","year":"2016","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bbcan.2020.188486_bb0745","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/2162402X.2019.1594555","article-title":"Tumor lysis with LTX-401 creates anticancer immunity","volume":"8","author":"Xie","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bbcan.2020.188486_bb0750","first-page":"139","article-title":"The novel oncolytic compound LTX-401 induces antitumor immune responses in experimental hepatocellular carcinoma","volume":"14","author":"Mauseth","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbcan.2020.188486_bb0755","first-page":"1","article-title":"Advances in anti-tumor treatments targeting the CD47\/SIRP\u03b1 Axis","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0760","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1001796","article-title":"CD47 agonist peptides induce programmed cell death in refractory chronic lymphocytic leukemia B cells via PLC\u03b31 activation: evidence from mice and humans","volume":"12","author":"Martinez-Torres","year":"2015","journal-title":"PLoS Med."},{"key":"10.1016\/j.bbcan.2020.188486_bb0765","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/cas.13885","article-title":"CD47 agonist peptide PKHB1 induces immunogenic cell death in T-cell acute lymphoblastic leukemia cells","volume":"110","author":"Uscanga-Palomeque","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbcan.2020.188486_bb0770","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/cas.14310","article-title":"Peptide analogues PKHB1 and 4N1K induce cell death through CD47-independent mechanisms","volume":"111","author":"Leclair","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbcan.2020.188486_bb0775","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1517\/14728220903431077","article-title":"Targeting AAC-11 in cancer therapy","volume":"14","author":"Faye","year":"2010","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bbcan.2020.188486_bb0780","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/emboj.2009.106","article-title":"The antiapoptotic protein AAC-11 interacts with and regulates Acinus-mediated DNA fragmentation","volume":"28","author":"Rigou","year":"2009","journal-title":"EMBO J."},{"key":"10.1016\/j.bbcan.2020.188486_bb0785","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.1158\/0008-5472.CAN-16-0302","article-title":"A cell-penetrating peptide targeting AAC-11 specifically induces cancer cells death","volume":"76","author":"Jagot-Lacoussiere","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2020.188486_bb0790","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0201220","article-title":"The anticancer peptide RT53 induces immunogenic cell death","volume":"13","author":"Pasquereau-Kotula","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2020.188486_bb0795","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1517\/17425255.2011.574126","article-title":"Stability of peptides and therapeutic success in cancer","volume":"7","author":"Pernot","year":"2011","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0800","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jconrel.2018.11.004","article-title":"Peptide-based targeted therapeutics: focus on cancer treatment","volume":"292","author":"Araste","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbcan.2020.188486_bb0805","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00726-005-0289-3","article-title":"Strategies to improve plasma half life time of peptide and protein drugs","volume":"30","author":"Werle","year":"2006","journal-title":"Amino Acids"},{"key":"10.1016\/j.bbcan.2020.188486_bb0810","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1208\/s12248-014-9687-3","article-title":"Strategic approaches to optimizing peptide ADME properties","volume":"17","author":"Di","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.bbcan.2020.188486_bb0815","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20235850","article-title":"Self-assembling peptides and their application in the treatment of diseases","volume":"20","author":"Lee","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2020.188486_bb0820","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aai8030","article-title":"Tyrosine kinase blocking collagen IV\u2013derived peptide suppresses ocular neovascularization and vascular leakage","volume":"9","author":"Lima e Silva","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbcan.2020.188486_bb0825","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41573-019-0053-0","article-title":"Advances in oral peptide therapeutics","volume":"19","author":"Drucker","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbcan.2020.188486_bb0830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2020.188486_bb0835","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nri.2017.76","article-title":"Single-cell RNA sequencing to explore immune cell heterogeneity","volume":"18","author":"Papalexi","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0840","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.it.2019.09.004","article-title":"Immunology driven by large-scale single-cell sequencing","volume":"40","author":"Gomes","year":"2019","journal-title":"Trends Immunol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0845","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2019.01146","article-title":"Tumor associated neutrophils. their role in tumorigenesis, metastasis, prognosis and therapy","volume":"9","author":"Masucci","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0850","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-019-0770-1","article-title":"Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy","volume":"12","author":"Liu","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0855","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2020.188486_bb0860","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2020.188486_bb0865","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1158\/0008-5472.CAN-12-4354","article-title":"Vascular normalization as an emerging strategy to enhance cancer immunotherapy","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2020.188486_bb0870","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41419-017-0061-0","article-title":"Defining the role of the tumor vasculature in antitumor immunity and immunotherapy","volume":"9","author":"Schaaf","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2020.188486_bb0875","doi-asserted-by":"crossref","first-page":"1760685","DOI":"10.1080\/2162402X.2020.1760685","article-title":"Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide","volume":"9","author":"Mirando","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bbcan.2020.188486_bb0880","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.2174\/138920111796117300","article-title":"Anti-Angiogenic peptides for cancer therapeutics","volume":"12","author":"Rosca","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.bbcan.2020.188486_bb0885","doi-asserted-by":"crossref","first-page":"13775","DOI":"10.1073\/pnas.0803241105","article-title":"A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells","volume":"105","author":"Karagiannis","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2020.188486_bb0890","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1016\/j.bmc.2017.06.052","article-title":"Therapeutic peptides: historical perspectives, current development trends, and future directions","volume":"26","author":"Lau","year":"2018","journal-title":"Bioorgan. Med. Chem."},{"key":"10.1016\/j.bbcan.2020.188486_bb0895","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/S1470-2045(19)30026-9","article-title":"Immunotherapy and targeted therapy combinations in metastatic breast cancer","volume":"20","author":"Esteva","year":"2019","journal-title":"Lancet Oncol."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X20302055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X20302055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T04:40:37Z","timestamp":1759639237000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X20302055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":179,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0304419X20302055"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2020.188486","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peptides that immunoactivate the tumor microenvironment","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2020.188486","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"188486"}}